Clinical Trial Update: Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing hypofractionated versus conventionally fractionated concurrent chemoradiotherapy for limited-disease small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Carcinoma, Small Cell, Lung Neoplasms | Phase 3 | Status: UNKNOWN